<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16618">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870609</url>
  </required_header>
  <id_info>
    <org_study_id>VS-6063-202</org_study_id>
    <nct_id>NCT01870609</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma</brief_title>
  <acronym>COMMAND</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>New Zealand: Medsafe</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of
      defactinib (VS-6063) in subjects with malignant pleural mesothelioma (MPM) who have not
      progressed (confirmed partial response or stable disease) following ≥ 4 cycles of treatment
      with pemetrexed/cisplatin or pemetrexed/carboplatin. Prior to entry and randomization to the
      study, each subject must have tumor Merlin status(high or low) established by
      immunohistochemistry performed at a central laboratory. Subjects will be randomized in a 1:1
      ratio to receive oral VS-6063 400 mg twice per day, or matched placebo. Randomization will
      be stratified by tumor Merlin status (high versus low). Progression will be assessed both
      locally and by central review using the Response Evaluation Criteria In Solid Tumors
      (RECIST) Version 1.1. Subjects will continue to receive treatment until disease progression
      or other discontinuation criteria are met. Following documentation of nonfatal disease
      progression, all subjects will be followed for overall survival by telephone contact every 2
      months until end of life or the close of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo</measure>
    <time_frame>From randomization to end of life, an expected average of 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The median duration of OS will be estimated based on the 50th percentile of the Kaplan-Meier distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo</measure>
    <time_frame>From date of randomization to earliest documented date of progression, an expected average of 4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS will be calculated based on the stratified log-rank test, and will use Kaplan-Meier estimation methods for estimation of summary statistics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess Quality of Life (QoL) in subjects treated with defactinib (VS-6063) or placebo using the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)</measure>
    <time_frame>Every 3-4 weeks from baseline through end of treatment, an expected average of 4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>QoL will be assessed using the LCSS-Meso. The LCSS-Meso total score will be analyzed through a comparison of median area under the curve (AUC) between the 2 treatment groups using a Wilcoxon test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the objective response rate (ORR) in subjects receiving defactinib (VS-6063) or placebo.</measure>
    <time_frame>Every 6-8 weeks from baseline through end of treatment, an expected average of  4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR is measured as the best overall response assessed by central review using Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the time to new lesion in subjects receiving defactinib (VS-6063) or placebo</measure>
    <time_frame>Every 6-8 weeks from baseline until end of treatment, an expected average of  4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to new lesion will be calculated from the date of randomization to the time of CT scan documenting a new lesion or date of other unambiguous indicator of new lesion development.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the relationship of defactinib (VS-6063) pharmacokinetics (PK) and outcome</measure>
    <time_frame>Time points at Week 4, Week 7, Week 10 and Week 13</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters, including but not limited to plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2, compared with outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the population pharmacokinetics of defactinib (VS-6063) in subjects with malignant pleural mesothelioma</measure>
    <time_frame>Time points at Week 4, Week 7, Week 10 and Week 13</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters, including but not limited to plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the safety and tolerability of defactinib (VS-6063) in subjects with malignant pleural mesothelioma</measure>
    <time_frame>From start of treatment to end of treatment, an expected average of 4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECG change monitoring as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>defactinib (VS-6063)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo tablets, administered orally, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>defactinib (VS-6063)</intervention_name>
    <arm_group_label>defactinib (VS-6063)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic defactinib tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Able to understand and give written informed consent and comply with study
             procedures.

          -  2. Histologically proven diagnosis of MPM. All subjects must have biopsy material
             (archival tissue is acceptable) available for immunohistochemistry determination of
             Merlin status prior to enrollment.

          -  3. Evaluable disease, or measurable disease as assessed by RECIST version 1.1.

          -  4. Received only one prior chemotherapy regimen consisting of ≥ 4 cycles of
             pemetrexed/cisplatin or pemetrexed/carboplatin; subjects must have documentation of
             an ongoing response (confirmed PR or SD) following completion of this regimen.
             Subjects changing from cisplatin to carboplatin or vice versa within the same course
             of treatment because of platinum toxicity will be considered to have had first-line
             chemotherapy. Note: Subjects may have undergone previous surgical resection of their
             disease providing it was completed prior to initiation of chemotherapy.

          -  5. Received last dose of pemetrexed/cisplatin or pemetrexed/carboplatin therapy
             within ≤ 6 weeks of study entry.

          -  6. Have completed baseline quality of life evaluation as assessed by LCSS modified
             for mesothelioma

          -  7. Age ≥18 years.

          -  8. Life expectancy ≥3 months.

          -  9. All prior cytotoxic toxicities must have resolved to grade ≤ 1 prior to
             randomization.

          -  10. Performance status according to the Karnofsky Scale of ≥ 70% (after palliative
             measures such as pleural drainage).

          -  11. Corrected QT interval (QTc) &lt; 470 ms (as calculated by the Fridericia correction
             formula).

          -  12. Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L;
             absolute neutrophil count [ANC] ≥ 1.5 x 109/L) without the use of hematopoietic
             growth factors.

          -  13. Adequate renal function (creatinine ≤ 1.5 x ULN [upper limit of normal] or
             glomerular filtration rate of ≥ 50mL/min).

          -  14. Adequate hepatic function (total bilirubin ≤ 1.5 x ULN for the institution;
             aspartate transaminase [AST] and alanine transaminase [ALT] ≤ 2.5 x ULN).

          -  15. Men and women of childbearing potential must agree to use adequate
             contraception(double barrier birth control) for the duration of study therapy and for
             3 months after the last dose of VS-6063.

        Exclusion Criteria:

          -  1. Currently enrolled in (or completed within 30 days before study drug
             administration)another investigational drug study.

          -  2. GI condition that could interfere with the swallowing or absorption of study drug.

          -  3. History of upper GI bleeding, ulceration, or perforation within 12 months prior to
             the first dose of study drug.

          -  4. Known history of Gilbert's Syndrome.

          -  5. Known history of stroke or cerebrovascular accident within 6 months prior to the
             first dose of study drug.

          -  6. Subjects with known infection with human immunodeficiency virus or Acquired Immune
             Deficiency Syndrome (testing not required).

          -  7. Subjects with known infection with hepatitis A, B or C (testing not required).

          -  8. Any evidence of serious active infections.

          -  9. Major surgery within 28 days prior to the first dose of study drug.

          -  10. Uncontrolled or severe concurrent medical condition (including uncontrolled brain
             metastases). Stable brain metastases either previously treated or being treated with
             a stable dose of steroids and/or anticonvulsants (no dose change within 28 days prior
             to the first dose of study drug) will be allowed.

          -  11. Uncontrolled or severe cardiovascular disease, including myocardial infarct or
             unstable angina within 6 months prior to study treatment, New York Heart Association
             Class II or greater congestive heart failure, serious arrhythmias requiring
             medication for treatment, clinically significant pericardial disease, or cardiac
             amyloidosis.

          -  12 Known history of malignant hypertension.

          -  13. Psychiatric illness or social situations that would limit compliance with study
             requirements.

          -  14. History of another invasive malignancy in the last 5 years. Adequately treated
             noninvasive,non-melanoma skin cancers as well as in situ carcinoma of the cervix
             within the last 5 years will be allowed.

          -  15. Prior treatment with drugs an FAK inhibitor.

          -  16. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hull, RN, OCN</last_name>
      <phone>773-834-3137</phone>
    </contact>
    <investigator>
      <last_name>Hedy Kindler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronan Kelly</last_name>
      <phone>443-287-0005</phone>
    </contact>
    <contact_backup>
      <last_name>Charles Raines</last_name>
      <phone>410-502-3696</phone>
    </contact_backup>
    <investigator>
      <last_name>Julie Brahmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Calderon, RN</last_name>
      <phone>718-918-3577</phone>
    </contact>
    <investigator>
      <last_name>Richard Gralla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
      <phone>646-888-4656</phone>
    </contact>
    <investigator>
      <last_name>Marjorie Zauderer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Stevenson, MD</last_name>
      <phone>216-636-6888</phone>
    </contact>
    <investigator>
      <last_name>James Stevenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Jacobs-Small</last_name>
      <phone>215-662-8632</phone>
      <email>Mona.Jacobs-Small@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Alley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurin Priddy</last_name>
      <phone>214-648-1688</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Dowell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Innes-Rowe</last_name>
      <phone>08 63833280</phone>
    </contact>
    <investigator>
      <last_name>Anna Nowak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Cancer Institute</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally McCowatt</last_name>
      <phone>02 9463 1181</phone>
    </contact>
    <investigator>
      <last_name>Nick Pavlakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL - St. Luc</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Erculisse</last_name>
      <email>Vanessa.Erculisse@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Thierry Pieters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Decoene</last_name>
      <phone>+32 3 8214719</phone>
      <email>ann.decoene@uza.be</email>
    </contact>
    <investigator>
      <last_name>Jan Van Meerbeeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU, Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Scherpereel</last_name>
      <phone>00 33 3 20 44 56 12</phone>
    </contact>
    <investigator>
      <last_name>Arnaud Scherpereel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Planchard</last_name>
      <phone>00 33 1 42 11 45 64</phone>
    </contact>
    <investigator>
      <last_name>David Planchard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama Rousai Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Nobukazu Fujimoto</last_name>
      <phone>81-86-262-0131</phone>
    </contact>
    <investigator>
      <last_name>Takumi Kishimoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Mahn</last_name>
      <phone>+31(0)205127496</phone>
      <email>m.mahn@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Paul Baas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente, Enschede</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ms. M. Mulder, MSc</last_name>
      <phone>+31 6 31 67 58 46</phone>
      <email>M.Mulder@mst.nl</email>
    </contact>
    <investigator>
      <last_name>J. H. Schouwink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrs. A. L. Geel</last_name>
      <phone>+31 (0)107030323</phone>
      <email>a.geel@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Joachim G.J.V. Aerts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland Oncology Research Centre</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Sun</last_name>
      <email>Vsun@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Richard Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Malo Perez</last_name>
      <phone>+34 93 274 60 00</phone>
      <phone_ext>4375</phone_ext>
    </contact>
    <investigator>
      <last_name>Susana Cedres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Oncològic del Vallés Consorci Hospitalari Parc Tauli</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Garcia Ruiz</last_name>
      <phone>+34 93 724 00 84</phone>
    </contact>
    <investigator>
      <last_name>Yolanda Garcia Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte- Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Blanco</last_name>
      <phone>+34 91 756 79 84</phone>
      <phone_ext>4885</phone_ext>
    </contact>
    <investigator>
      <last_name>Cristobal Belda-Iniesta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronny Ohman</last_name>
      <phone>: +46 (0)46 17 10 00</phone>
    </contact>
    <investigator>
      <last_name>Ronny Ohman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Hillerdal</last_name>
      <phone>+46 (0)8 517 700 00</phone>
    </contact>
    <investigator>
      <last_name>Daniel Brodin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Ekman</last_name>
      <phone>+46 (0)18 611 00 00</phone>
    </contact>
    <investigator>
      <last_name>Simon Ekman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Coliof</last_name>
      <phone>+44 (0)1223 216083</phone>
      <email>cctc@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Gilligan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital Cardiff</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Jackson</last_name>
      <phone>+44 (0)2920 615888</phone>
      <phone_ext>6315</phone_ext>
      <email>Amanda.Jackson2@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jason Lester</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndsay Johnson</last_name>
      <phone>01254 516 339</phone>
      <email>lyndsay.johnson@meht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sunil Skaria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leicester</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kang</last_name>
      <phone>+44 (0)116 258 7598</phone>
      <email>Anita.Kang@uhl-tr.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Debbie Samuel</last_name>
      <phone>0116 204 7872</phone>
      <email>debbie.samuel@uhl-tr.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dean Fennell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Spicer, MD</last_name>
      <phone>+44 (0) 207188 4260</phone>
    </contact>
    <investigator>
      <last_name>James Spicer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Hillman</last_name>
      <phone>+44 (0) 2034657364</phone>
    </contact>
    <investigator>
      <last_name>Peter Szlosarek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Taylor</last_name>
      <phone>+44 (0)161 291 2829</phone>
      <email>paul.taylor@uhsm.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Barron</last_name>
      <phone>0191 213 8436</phone>
      <email>chris.barron@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew Hughes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Nolan</last_name>
      <phone>+44 (0)23 8079 6802</phone>
    </contact>
    <investigator>
      <last_name>Luke Nolan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
